Statin-Induced Cardioprotection Against Ischemia-Reperfusion Injury: Potential Drug-Drug Interactions. Lesson to be Learnt by Translating Results from Animal Models to the Clinical Settings

Gilad D. Birnbaum, Itamar Birnbaum, Yumei Ye, Yochai Birnbaum

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Numerous interventions have been shown to limit myocardial infarct size in animal models; however, most of these interventions have failed to have a significant effect in clinical trials. One potential explanation for the lack of efficacy in the clinical setting is that in bench models, a single intervention is studied without the background of other interventions or modalities. This is in contrast to the clinical setting in which new medications are added to the “standard of care” treatment that by now includes a growing number of medications. Drug-drug interaction may lead to alteration, dampening, augmenting or masking the effects of the intended intervention. We use the well described model of statin-induced myocardial protection to demonstrate potential interactions with agents which are commonly concomitantly used in patients with stable coronary artery disease and/or acute coronary syndromes. These interactions could potentially explain the reduced efficacy of statins in the clinical trials compared to the animal models. In particular, caffeine and aspirin could attenuate the infarct size limiting effects of statins; morphine could delay the onset of protection or mask the protective effect in patients with ST elevation myocardial infarction, whereas other anti-platelet agents (dipyridamole, cilostazol and ticagrelor) may augment (or mask) the effect due to their favorable effects on adenosine cell reuptake and intracellular cAMP levels. We recommend that after characterizing the effects of new modalities in single intervention bench research, studies should be repeated in the background of standard-of-care medications to assure that the magnitude of the effect is not altered before proceeding with clinical trials.

Original languageEnglish (US)
Pages (from-to)461-467
Number of pages7
JournalCardiovascular Drugs and Therapy
Volume29
Issue number5
DOIs
StatePublished - Aug 25 2015

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Reperfusion Injury
Drug Interactions
Animal Models
Clinical Trials
Standard of Care
Masks
Pharmaceutical Preparations
Dipyridamole
Acute Coronary Syndrome
Caffeine
Adenosine
Morphine
Aspirin
Coronary Artery Disease
Blood Platelets
Myocardial Infarction
Research
Therapeutics

Keywords

  • Adenosine
  • Animal models
  • Clinical trials
  • Cyclooxygenase-2
  • Diabetic drugs
  • Drug interaction
  • Infarct size
  • Morphine
  • Statins

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Statin-Induced Cardioprotection Against Ischemia-Reperfusion Injury : Potential Drug-Drug Interactions. Lesson to be Learnt by Translating Results from Animal Models to the Clinical Settings. / Birnbaum, Gilad D.; Birnbaum, Itamar; Ye, Yumei; Birnbaum, Yochai.

In: Cardiovascular Drugs and Therapy, Vol. 29, No. 5, 25.08.2015, p. 461-467.

Research output: Contribution to journalArticle

@article{3d439577236b4eb493beef8209f876d1,
title = "Statin-Induced Cardioprotection Against Ischemia-Reperfusion Injury: Potential Drug-Drug Interactions. Lesson to be Learnt by Translating Results from Animal Models to the Clinical Settings",
abstract = "Numerous interventions have been shown to limit myocardial infarct size in animal models; however, most of these interventions have failed to have a significant effect in clinical trials. One potential explanation for the lack of efficacy in the clinical setting is that in bench models, a single intervention is studied without the background of other interventions or modalities. This is in contrast to the clinical setting in which new medications are added to the “standard of care” treatment that by now includes a growing number of medications. Drug-drug interaction may lead to alteration, dampening, augmenting or masking the effects of the intended intervention. We use the well described model of statin-induced myocardial protection to demonstrate potential interactions with agents which are commonly concomitantly used in patients with stable coronary artery disease and/or acute coronary syndromes. These interactions could potentially explain the reduced efficacy of statins in the clinical trials compared to the animal models. In particular, caffeine and aspirin could attenuate the infarct size limiting effects of statins; morphine could delay the onset of protection or mask the protective effect in patients with ST elevation myocardial infarction, whereas other anti-platelet agents (dipyridamole, cilostazol and ticagrelor) may augment (or mask) the effect due to their favorable effects on adenosine cell reuptake and intracellular cAMP levels. We recommend that after characterizing the effects of new modalities in single intervention bench research, studies should be repeated in the background of standard-of-care medications to assure that the magnitude of the effect is not altered before proceeding with clinical trials.",
keywords = "Adenosine, Animal models, Clinical trials, Cyclooxygenase-2, Diabetic drugs, Drug interaction, Infarct size, Morphine, Statins",
author = "Birnbaum, {Gilad D.} and Itamar Birnbaum and Yumei Ye and Yochai Birnbaum",
year = "2015",
month = "8",
day = "25",
doi = "10.1007/s10557-015-6615-4",
language = "English (US)",
volume = "29",
pages = "461--467",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "5",

}

TY - JOUR

T1 - Statin-Induced Cardioprotection Against Ischemia-Reperfusion Injury

T2 - Potential Drug-Drug Interactions. Lesson to be Learnt by Translating Results from Animal Models to the Clinical Settings

AU - Birnbaum, Gilad D.

AU - Birnbaum, Itamar

AU - Ye, Yumei

AU - Birnbaum, Yochai

PY - 2015/8/25

Y1 - 2015/8/25

N2 - Numerous interventions have been shown to limit myocardial infarct size in animal models; however, most of these interventions have failed to have a significant effect in clinical trials. One potential explanation for the lack of efficacy in the clinical setting is that in bench models, a single intervention is studied without the background of other interventions or modalities. This is in contrast to the clinical setting in which new medications are added to the “standard of care” treatment that by now includes a growing number of medications. Drug-drug interaction may lead to alteration, dampening, augmenting or masking the effects of the intended intervention. We use the well described model of statin-induced myocardial protection to demonstrate potential interactions with agents which are commonly concomitantly used in patients with stable coronary artery disease and/or acute coronary syndromes. These interactions could potentially explain the reduced efficacy of statins in the clinical trials compared to the animal models. In particular, caffeine and aspirin could attenuate the infarct size limiting effects of statins; morphine could delay the onset of protection or mask the protective effect in patients with ST elevation myocardial infarction, whereas other anti-platelet agents (dipyridamole, cilostazol and ticagrelor) may augment (or mask) the effect due to their favorable effects on adenosine cell reuptake and intracellular cAMP levels. We recommend that after characterizing the effects of new modalities in single intervention bench research, studies should be repeated in the background of standard-of-care medications to assure that the magnitude of the effect is not altered before proceeding with clinical trials.

AB - Numerous interventions have been shown to limit myocardial infarct size in animal models; however, most of these interventions have failed to have a significant effect in clinical trials. One potential explanation for the lack of efficacy in the clinical setting is that in bench models, a single intervention is studied without the background of other interventions or modalities. This is in contrast to the clinical setting in which new medications are added to the “standard of care” treatment that by now includes a growing number of medications. Drug-drug interaction may lead to alteration, dampening, augmenting or masking the effects of the intended intervention. We use the well described model of statin-induced myocardial protection to demonstrate potential interactions with agents which are commonly concomitantly used in patients with stable coronary artery disease and/or acute coronary syndromes. These interactions could potentially explain the reduced efficacy of statins in the clinical trials compared to the animal models. In particular, caffeine and aspirin could attenuate the infarct size limiting effects of statins; morphine could delay the onset of protection or mask the protective effect in patients with ST elevation myocardial infarction, whereas other anti-platelet agents (dipyridamole, cilostazol and ticagrelor) may augment (or mask) the effect due to their favorable effects on adenosine cell reuptake and intracellular cAMP levels. We recommend that after characterizing the effects of new modalities in single intervention bench research, studies should be repeated in the background of standard-of-care medications to assure that the magnitude of the effect is not altered before proceeding with clinical trials.

KW - Adenosine

KW - Animal models

KW - Clinical trials

KW - Cyclooxygenase-2

KW - Diabetic drugs

KW - Drug interaction

KW - Infarct size

KW - Morphine

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84946494364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946494364&partnerID=8YFLogxK

U2 - 10.1007/s10557-015-6615-4

DO - 10.1007/s10557-015-6615-4

M3 - Article

C2 - 26303765

AN - SCOPUS:84946494364

VL - 29

SP - 461

EP - 467

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 5

ER -